文献速递心脑血管急症重症综合管理与镇静镇痛

以CPPopt为目标真的能改善脑血管反应性吗?COGiTATE随机对照试验的二次分析

Does Targeting CPP at CPPopt Actually Improve Cerebrovascular Reactivity? A Secondary Analysis of the COGiTATE Randomized Controlled Trial.
PubMed 文献 · Neurocrit Care · 2024-12-02
一句话结论在COGiTATE试验的二次分析中,以CPPopt为目标时ΔPRx中位数显著更低(p<0.001),提示脑血管反应性可能改善。

本文为COGiTATE随机对照试验的二次分析,纳入对照组28例和干预组32例需要颅内压管理的TBI患者,比较每小时平均ΔPRx(PRx减去PRxopt)在整体自身调节保留(PRxopt为负)期间两组间的差异,并比较干预组内ΔCPP在-5至+5 mmHg范围内外时PRx的差异。结果:PRxopt为负时干预组ΔPRx中位数显著低于对照组(Mann-Whitney U检验,p<0.001);干预组每例患者在CPP接近CPPopt目标期间PRx中位数更低(Wilcoxon检验,p<0.001)。尽管总平均PRx无统计学显著差异,结果提示以CPPopt为目标可能改善TBI患者的脑血管反应性。

要点

  • COGiTATE二次分析纳入对照组28例、干预组32例需颅内压管理的TBI患者,比较每小时平均ΔPRx。
  • PRxopt为负(自身调节整体保留)期间,干预组ΔPRx中位数显著低于对照组(Mann-Whitney U检验,p<0.001)。
  • 干预组内,CPP接近CPPopt目标(ΔCPP在-5至+5 mmHg)时PRx中位数低于ΔCPP在此范围外时(Wilcoxon检验,p<0.001)。
  • 原试验中干预组(CPP目标=CPPopt)与对照组(CPP目标=60-70 mmHg)的总平均PRx无差异。
  • 作者认为以CPPopt为目标可能改善TBI患者的脑血管反应性,并为未来自身调节指导方案与试验设计提供参考。

适用人群与场景

  • 需要颅内压管理的创伤性脑损伤(TBI)患者,来自COGiTATE随机对照试验,二次分析纳入对照组28例和干预组32例。

诊断标准与关键阈值

  • 以ΔPRx(PRx减去PRxopt,PRxopt为CPPopt时的PRx)作为每小时平均指标进行比较。
  • 聚焦于整体自身调节保留/均匀的时段,即PRxopt为负的时段。
  • 干预组内以ΔCPP(CPP减去CPPopt目标)在-5至+5 mmHg范围内为接近目标。

研究设计与关键结果

  • 研究类型:COGiTATE随机对照试验的二次分析;样本量:对照组28例、干预组32例;人群:需要颅内压管理的TBI患者;干预:干预组CPP目标=CPPopt,对照组CPP目标=60-70 mmHg。
  • 主要终点结果:PRxopt为负时,干预组ΔPRx中位数显著低于对照组(Mann-Whitney U检验,p<0.001)。
  • 干预组内比较:每例患者在CPP接近CPPopt目标(ΔCPP在-5至+5 mmHg)期间PRx中位数低于ΔCPP在此范围外期间(Wilcoxon检验,p<0.001)。
  • 原试验报告干预组与对照组的总平均PRx无统计学显著差异。

证据类型、等级与局限

  • 证据类型:随机对照试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,尽管总平均PRx无统计学显著差异,以CPPopt为目标可能提供改善TBI患者脑血管反应性的途径,为针对该问题的试验提供合理干预。
  • 作者认为,本研究为未来临床方案和试验设计中自身调节指导管理需考虑的PRx/CPP关系方面提供了见解。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The 'CPPopt-Guided Therapy: Assessment of Target Effectiveness' (COGiTATE) randomised controlled trial demonstrated the feasibility and safety of targeting an automated cerebral perfusion pressure (CPP) tailored to optimize cerebrovascular autoregulation (CPPopt) in patients with traumatic brain injury (TBI) requiring intracranial pressure management. The average values of the autoregulation index known as the pressure reactivity index (PRx) were not different between the intervention (CPP target = CPPopt) and control (CPP target = 60-70 mmHg) groups of the trial. This secondary analysis was performed to investigate whether: (1) in the intervention group, PRx was closer to PRxopt (PRx at CPPopt) values, indicating a more preserved reactivity, as opposed to in the control group; (2) in the intervention group, patients experienced lower hourly PRx when CPP was close to the CPPopt-based target.

METHODS: We analyzed data from the 28 and 32 patients randomized to the control and intervention groups of the COGiTATE study, respectively. We compared hourly averaged ΔPRx (PRx minus PRxopt, where PRxopt is PRx at CPPopt) between the two groups, focusing on periods of globally preserved/homogeneous autoregulation (negative PRxopt). For each patient in the intervention group, PRx values in periods when ΔCPP (CPP minus CPPopt target) was between -5 and + 5 mm Hg were compared to values in periods when ΔCPP was outside this range.

RESULTS: The median ΔPRx was significantly lower in the intervention group for negative PRxopt (Mann-Whitney U-test, p < 0.001). For each patient in this group, the median PRx was lower in periods when CPP was close to the CPPopt-based target (Wilcoxon test, p < 0.001).

CONCLUSIONS: Despite no statistically significant difference in the grand mean PRx, our results suggest that targeting CPPopt does provide a way of improving cerebrovascular reactivity in patients with TBI, offering a rational intervention for trials that address this issue. We also bring insight into aspects of the PRx/CPP relationship that should be considered for autoregulation-guided management for future clinical protocols and trials design.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Beqiri E, Tas J, Czosnyka M, et al. Does Targeting CPP at CPPopt Actually Improve Cerebrovascular Reactivity? A Secondary Analysis of the COGiTATE Randomized Controlled Trial. Neurocrit Care. 2024. PMID: 39623160. doi:10.1007/s12028-024-02168-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。